The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Novel Antiviral Drugs Market Research Report 2025
Synopsis
The mechanism of action of antiviral drugs is mainly to inhibit the entry of viral particles into host cells and to inhibit the early stages of viral replication. There is also an inhibitor of DNA polymerase, which is mainly due to its ability to inhibit viral coding. At present, new antiviral drugs are actively seeking host factors, both in the initial stage of viral infection and in the later stages of nuclear transport of viral RNP complexes, to produce new drugs with new modes of action without drug resistance.
The global Novel Antiviral Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Novel Antiviral Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Novel Antiviral Drugs.
Report Scope
The Novel Antiviral Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Novel Antiviral Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Novel Antiviral Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche Holding AG
GlaxoSmithKline
Bristol-Myers Squibb
AbbVie
Johnson & Johnson
Merck & Co
Novartis
Dr Reddy’s
Gilead Sciences
Aurobindo Pharma
Cipla
Segment by Type
Reverse Transcriptase Inhibitors
Protease Inhibitors
Fusion Inhibitors
Immune System Modulators
Other
Segment by Application
Hepatitis Therapeutics
HIV/AIDS Therapeutics
Herpes Therapeutics
Influenza Therapeutics
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Novel Antiviral Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The mechanism of action of antiviral drugs is mainly to inhibit the entry of viral particles into host cells and to inhibit the early stages of viral replication. There is also an inhibitor of DNA polymerase, which is mainly due to its ability to inhibit viral coding. At present, new antiviral drugs are actively seeking host factors, both in the initial stage of viral infection and in the later stages of nuclear transport of viral RNP complexes, to produce new drugs with new modes of action without drug resistance.
The global Novel Antiviral Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Novel Antiviral Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Novel Antiviral Drugs.
Report Scope
The Novel Antiviral Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Novel Antiviral Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Novel Antiviral Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche Holding AG
GlaxoSmithKline
Bristol-Myers Squibb
AbbVie
Johnson & Johnson
Merck & Co
Novartis
Dr Reddy’s
Gilead Sciences
Aurobindo Pharma
Cipla
Segment by Type
Reverse Transcriptase Inhibitors
Protease Inhibitors
Fusion Inhibitors
Immune System Modulators
Other
Segment by Application
Hepatitis Therapeutics
HIV/AIDS Therapeutics
Herpes Therapeutics
Influenza Therapeutics
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Novel Antiviral Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Novel Antiviral Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Reverse Transcriptase Inhibitors
1.2.3 Protease Inhibitors
1.2.4 Fusion Inhibitors
1.2.5 Immune System Modulators
1.2.6 Other
1.3 Market by Application
1.3.1 Global Novel Antiviral Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hepatitis Therapeutics
1.3.3 HIV/AIDS Therapeutics
1.3.4 Herpes Therapeutics
1.3.5 Influenza Therapeutics
1.3.6 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Novel Antiviral Drugs Market Perspective (2019-2030)
2.2 Novel Antiviral Drugs Growth Trends by Region
2.2.1 Global Novel Antiviral Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Novel Antiviral Drugs Historic Market Size by Region (2019-2024)
2.2.3 Novel Antiviral Drugs Forecasted Market Size by Region (2025-2030)
2.3 Novel Antiviral Drugs Market Dynamics
2.3.1 Novel Antiviral Drugs Industry Trends
2.3.2 Novel Antiviral Drugs Market Drivers
2.3.3 Novel Antiviral Drugs Market Challenges
2.3.4 Novel Antiviral Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Novel Antiviral Drugs Players by Revenue
3.1.1 Global Top Novel Antiviral Drugs Players by Revenue (2019-2024)
3.1.2 Global Novel Antiviral Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Novel Antiviral Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Novel Antiviral Drugs Revenue
3.4 Global Novel Antiviral Drugs Market Concentration Ratio
3.4.1 Global Novel Antiviral Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Novel Antiviral Drugs Revenue in 2023
3.5 Novel Antiviral Drugs Key Players Head office and Area Served
3.6 Key Players Novel Antiviral Drugs Product Solution and Service
3.7 Date of Enter into Novel Antiviral Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Novel Antiviral Drugs Breakdown Data by Type
4.1 Global Novel Antiviral Drugs Historic Market Size by Type (2019-2024)
4.2 Global Novel Antiviral Drugs Forecasted Market Size by Type (2025-2030)
5 Novel Antiviral Drugs Breakdown Data by Application
5.1 Global Novel Antiviral Drugs Historic Market Size by Application (2019-2024)
5.2 Global Novel Antiviral Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Novel Antiviral Drugs Market Size (2019-2030)
6.2 North America Novel Antiviral Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Novel Antiviral Drugs Market Size by Country (2019-2024)
6.4 North America Novel Antiviral Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Novel Antiviral Drugs Market Size (2019-2030)
7.2 Europe Novel Antiviral Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Novel Antiviral Drugs Market Size by Country (2019-2024)
7.4 Europe Novel Antiviral Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Novel Antiviral Drugs Market Size (2019-2030)
8.2 Asia-Pacific Novel Antiviral Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Novel Antiviral Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific Novel Antiviral Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Novel Antiviral Drugs Market Size (2019-2030)
9.2 Latin America Novel Antiviral Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Novel Antiviral Drugs Market Size by Country (2019-2024)
9.4 Latin America Novel Antiviral Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Novel Antiviral Drugs Market Size (2019-2030)
10.2 Middle East & Africa Novel Antiviral Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Novel Antiviral Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa Novel Antiviral Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche Holding AG
11.1.1 Roche Holding AG Company Detail
11.1.2 Roche Holding AG Business Overview
11.1.3 Roche Holding AG Novel Antiviral Drugs Introduction
11.1.4 Roche Holding AG Revenue in Novel Antiviral Drugs Business (2019-2024)
11.1.5 Roche Holding AG Recent Development
11.2 GlaxoSmithKline
11.2.1 GlaxoSmithKline Company Detail
11.2.2 GlaxoSmithKline Business Overview
11.2.3 GlaxoSmithKline Novel Antiviral Drugs Introduction
11.2.4 GlaxoSmithKline Revenue in Novel Antiviral Drugs Business (2019-2024)
11.2.5 GlaxoSmithKline Recent Development
11.3 Bristol-Myers Squibb
11.3.1 Bristol-Myers Squibb Company Detail
11.3.2 Bristol-Myers Squibb Business Overview
11.3.3 Bristol-Myers Squibb Novel Antiviral Drugs Introduction
11.3.4 Bristol-Myers Squibb Revenue in Novel Antiviral Drugs Business (2019-2024)
11.3.5 Bristol-Myers Squibb Recent Development
11.4 AbbVie
11.4.1 AbbVie Company Detail
11.4.2 AbbVie Business Overview
11.4.3 AbbVie Novel Antiviral Drugs Introduction
11.4.4 AbbVie Revenue in Novel Antiviral Drugs Business (2019-2024)
11.4.5 AbbVie Recent Development
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Detail
11.5.2 Johnson & Johnson Business Overview
11.5.3 Johnson & Johnson Novel Antiviral Drugs Introduction
11.5.4 Johnson & Johnson Revenue in Novel Antiviral Drugs Business (2019-2024)
11.5.5 Johnson & Johnson Recent Development
11.6 Merck & Co
11.6.1 Merck & Co Company Detail
11.6.2 Merck & Co Business Overview
11.6.3 Merck & Co Novel Antiviral Drugs Introduction
11.6.4 Merck & Co Revenue in Novel Antiviral Drugs Business (2019-2024)
11.6.5 Merck & Co Recent Development
11.7 Novartis
11.7.1 Novartis Company Detail
11.7.2 Novartis Business Overview
11.7.3 Novartis Novel Antiviral Drugs Introduction
11.7.4 Novartis Revenue in Novel Antiviral Drugs Business (2019-2024)
11.7.5 Novartis Recent Development
11.8 Dr Reddy’s
11.8.1 Dr Reddy’s Company Detail
11.8.2 Dr Reddy’s Business Overview
11.8.3 Dr Reddy’s Novel Antiviral Drugs Introduction
11.8.4 Dr Reddy’s Revenue in Novel Antiviral Drugs Business (2019-2024)
11.8.5 Dr Reddy’s Recent Development
11.9 Gilead Sciences
11.9.1 Gilead Sciences Company Detail
11.9.2 Gilead Sciences Business Overview
11.9.3 Gilead Sciences Novel Antiviral Drugs Introduction
11.9.4 Gilead Sciences Revenue in Novel Antiviral Drugs Business (2019-2024)
11.9.5 Gilead Sciences Recent Development
11.10 Aurobindo Pharma
11.10.1 Aurobindo Pharma Company Detail
11.10.2 Aurobindo Pharma Business Overview
11.10.3 Aurobindo Pharma Novel Antiviral Drugs Introduction
11.10.4 Aurobindo Pharma Revenue in Novel Antiviral Drugs Business (2019-2024)
11.10.5 Aurobindo Pharma Recent Development
11.11 Cipla
11.11.1 Cipla Company Detail
11.11.2 Cipla Business Overview
11.11.3 Cipla Novel Antiviral Drugs Introduction
11.11.4 Cipla Revenue in Novel Antiviral Drugs Business (2019-2024)
11.11.5 Cipla Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Novel Antiviral Drugs Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Reverse Transcriptase Inhibitors
Table 3. Key Players of Protease Inhibitors
Table 4. Key Players of Fusion Inhibitors
Table 5. Key Players of Immune System Modulators
Table 6. Key Players of Other
Table 7. Global Novel Antiviral Drugs Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global Novel Antiviral Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 9. Global Novel Antiviral Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 10. Global Novel Antiviral Drugs Market Share by Region (2019-2024)
Table 11. Global Novel Antiviral Drugs Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 12. Global Novel Antiviral Drugs Market Share by Region (2025-2030)
Table 13. Novel Antiviral Drugs Market Trends
Table 14. Novel Antiviral Drugs Market Drivers
Table 15. Novel Antiviral Drugs Market Challenges
Table 16. Novel Antiviral Drugs Market Restraints
Table 17. Global Novel Antiviral Drugs Revenue by Players (2019-2024) & (US$ Million)
Table 18. Global Novel Antiviral Drugs Market Share by Players (2019-2024)
Table 19. Global Top Novel Antiviral Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Novel Antiviral Drugs as of 2023)
Table 20. Ranking of Global Top Novel Antiviral Drugs Companies by Revenue (US$ Million) in 2023
Table 21. Global 5 Largest Players Market Share by Novel Antiviral Drugs Revenue (CR5 and HHI) & (2019-2024)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Novel Antiviral Drugs Product Solution and Service
Table 24. Date of Enter into Novel Antiviral Drugs Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Novel Antiviral Drugs Market Size by Type (2019-2024) & (US$ Million)
Table 27. Global Novel Antiviral Drugs Revenue Market Share by Type (2019-2024)
Table 28. Global Novel Antiviral Drugs Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 29. Global Novel Antiviral Drugs Revenue Market Share by Type (2025-2030)
Table 30. Global Novel Antiviral Drugs Market Size by Application (2019-2024) & (US$ Million)
Table 31. Global Novel Antiviral Drugs Revenue Market Share by Application (2019-2024)
Table 32. Global Novel Antiviral Drugs Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 33. Global Novel Antiviral Drugs Revenue Market Share by Application (2025-2030)
Table 34. North America Novel Antiviral Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. North America Novel Antiviral Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 36. North America Novel Antiviral Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 37. Europe Novel Antiviral Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 38. Europe Novel Antiviral Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 39. Europe Novel Antiviral Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 40. Asia-Pacific Novel Antiviral Drugs Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 41. Asia-Pacific Novel Antiviral Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 42. Asia-Pacific Novel Antiviral Drugs Market Size by Region (2025-2030) & (US$ Million)
Table 43. Latin America Novel Antiviral Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Latin America Novel Antiviral Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 45. Latin America Novel Antiviral Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 46. Middle East & Africa Novel Antiviral Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 47. Middle East & Africa Novel Antiviral Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 48. Middle East & Africa Novel Antiviral Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 49. Roche Holding AG Company Detail
Table 50. Roche Holding AG Business Overview
Table 51. Roche Holding AG Novel Antiviral Drugs Product
Table 52. Roche Holding AG Revenue in Novel Antiviral Drugs Business (2019-2024) & (US$ Million)
Table 53. Roche Holding AG Recent Development
Table 54. GlaxoSmithKline Company Detail
Table 55. GlaxoSmithKline Business Overview
Table 56. GlaxoSmithKline Novel Antiviral Drugs Product
Table 57. GlaxoSmithKline Revenue in Novel Antiviral Drugs Business (2019-2024) & (US$ Million)
Table 58. GlaxoSmithKline Recent Development
Table 59. Bristol-Myers Squibb Company Detail
Table 60. Bristol-Myers Squibb Business Overview
Table 61. Bristol-Myers Squibb Novel Antiviral Drugs Product
Table 62. Bristol-Myers Squibb Revenue in Novel Antiviral Drugs Business (2019-2024) & (US$ Million)
Table 63. Bristol-Myers Squibb Recent Development
Table 64. AbbVie Company Detail
Table 65. AbbVie Business Overview
Table 66. AbbVie Novel Antiviral Drugs Product
Table 67. AbbVie Revenue in Novel Antiviral Drugs Business (2019-2024) & (US$ Million)
Table 68. AbbVie Recent Development
Table 69. Johnson & Johnson Company Detail
Table 70. Johnson & Johnson Business Overview
Table 71. Johnson & Johnson Novel Antiviral Drugs Product
Table 72. Johnson & Johnson Revenue in Novel Antiviral Drugs Business (2019-2024) & (US$ Million)
Table 73. Johnson & Johnson Recent Development
Table 74. Merck & Co Company Detail
Table 75. Merck & Co Business Overview
Table 76. Merck & Co Novel Antiviral Drugs Product
Table 77. Merck & Co Revenue in Novel Antiviral Drugs Business (2019-2024) & (US$ Million)
Table 78. Merck & Co Recent Development
Table 79. Novartis Company Detail
Table 80. Novartis Business Overview
Table 81. Novartis Novel Antiviral Drugs Product
Table 82. Novartis Revenue in Novel Antiviral Drugs Business (2019-2024) & (US$ Million)
Table 83. Novartis Recent Development
Table 84. Dr Reddy’s Company Detail
Table 85. Dr Reddy’s Business Overview
Table 86. Dr Reddy’s Novel Antiviral Drugs Product
Table 87. Dr Reddy’s Revenue in Novel Antiviral Drugs Business (2019-2024) & (US$ Million)
Table 88. Dr Reddy’s Recent Development
Table 89. Gilead Sciences Company Detail
Table 90. Gilead Sciences Business Overview
Table 91. Gilead Sciences Novel Antiviral Drugs Product
Table 92. Gilead Sciences Revenue in Novel Antiviral Drugs Business (2019-2024) & (US$ Million)
Table 93. Gilead Sciences Recent Development
Table 94. Aurobindo Pharma Company Detail
Table 95. Aurobindo Pharma Business Overview
Table 96. Aurobindo Pharma Novel Antiviral Drugs Product
Table 97. Aurobindo Pharma Revenue in Novel Antiviral Drugs Business (2019-2024) & (US$ Million)
Table 98. Aurobindo Pharma Recent Development
Table 99. Cipla Company Detail
Table 100. Cipla Business Overview
Table 101. Cipla Novel Antiviral Drugs Product
Table 102. Cipla Revenue in Novel Antiviral Drugs Business (2019-2024) & (US$ Million)
Table 103. Cipla Recent Development
Table 104. Research Programs/Design for This Report
Table 105. Key Data Information from Secondary Sources
Table 106. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Novel Antiviral Drugs Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Novel Antiviral Drugs Market Share by Type: 2023 VS 2030
Figure 3. Reverse Transcriptase Inhibitors Features
Figure 4. Protease Inhibitors Features
Figure 5. Fusion Inhibitors Features
Figure 6. Immune System Modulators Features
Figure 7. Other Features
Figure 8. Global Novel Antiviral Drugs Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 9. Global Novel Antiviral Drugs Market Share by Application: 2023 VS 2030
Figure 10. Hepatitis Therapeutics Case Studies
Figure 11. HIV/AIDS Therapeutics Case Studies
Figure 12. Herpes Therapeutics Case Studies
Figure 13. Influenza Therapeutics Case Studies
Figure 14. Other Case Studies
Figure 15. Novel Antiviral Drugs Report Years Considered
Figure 16. Global Novel Antiviral Drugs Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 17. Global Novel Antiviral Drugs Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 18. Global Novel Antiviral Drugs Market Share by Region: 2023 VS 2030
Figure 19. Global Novel Antiviral Drugs Market Share by Players in 2023
Figure 20. Global Top Novel Antiviral Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Novel Antiviral Drugs as of 2023)
Figure 21. The Top 10 and 5 Players Market Share by Novel Antiviral Drugs Revenue in 2023
Figure 22. North America Novel Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. North America Novel Antiviral Drugs Market Share by Country (2019-2030)
Figure 24. United States Novel Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Canada Novel Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Europe Novel Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Europe Novel Antiviral Drugs Market Share by Country (2019-2030)
Figure 28. Germany Novel Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. France Novel Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. U.K. Novel Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Italy Novel Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Russia Novel Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Nordic Countries Novel Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Asia-Pacific Novel Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Asia-Pacific Novel Antiviral Drugs Market Share by Region (2019-2030)
Figure 36. China Novel Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Japan Novel Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. South Korea Novel Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Southeast Asia Novel Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. India Novel Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Australia Novel Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Latin America Novel Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Latin America Novel Antiviral Drugs Market Share by Country (2019-2030)
Figure 44. Mexico Novel Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Brazil Novel Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Middle East & Africa Novel Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Middle East & Africa Novel Antiviral Drugs Market Share by Country (2019-2030)
Figure 48. Turkey Novel Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 49. Saudi Arabia Novel Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 50. Roche Holding AG Revenue Growth Rate in Novel Antiviral Drugs Business (2019-2024)
Figure 51. GlaxoSmithKline Revenue Growth Rate in Novel Antiviral Drugs Business (2019-2024)
Figure 52. Bristol-Myers Squibb Revenue Growth Rate in Novel Antiviral Drugs Business (2019-2024)
Figure 53. AbbVie Revenue Growth Rate in Novel Antiviral Drugs Business (2019-2024)
Figure 54. Johnson & Johnson Revenue Growth Rate in Novel Antiviral Drugs Business (2019-2024)
Figure 55. Merck & Co Revenue Growth Rate in Novel Antiviral Drugs Business (2019-2024)
Figure 56. Novartis Revenue Growth Rate in Novel Antiviral Drugs Business (2019-2024)
Figure 57. Dr Reddy’s Revenue Growth Rate in Novel Antiviral Drugs Business (2019-2024)
Figure 58. Gilead Sciences Revenue Growth Rate in Novel Antiviral Drugs Business (2019-2024)
Figure 59. Aurobindo Pharma Revenue Growth Rate in Novel Antiviral Drugs Business (2019-2024)
Figure 60. Cipla Revenue Growth Rate in Novel Antiviral Drugs Business (2019-2024)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
